Skip to content

Posts tagged ‘Alpharadin’

Are you adapting to the changing prostate cancer market?

February 10th, 2012


The prostate cancer market continues to evolve at a fast pace.  Companies with products on the market or in development will need to adapt their marketing strategy to the changing prostate cancer market dynamics.  Some of the recent news includes:

MDV3100 shows 4.8 improvement in median overall survival

Sally Church, PhD on Pharma Strategy Blog interviewed David Hung, MD CEO of Medivation and discussed the MDV3100 clinical trial data presented at ASCO GU.

Sally has been following the development of MDV3100 for a while, and previously interviewed Dr Charles Sawyers one of the co-developers.

MDV3100 showed an improvement in median overall survival of 4.8 months in advanced prostate cancer, and offers a number of significant advantages over abiraterone acetate (Zytiga) due to its different mechanism of action on the androgen receptor.

One of the advantages is it’s ability to target splice variants:

You can read more about MDV3100 on Pharma Strategy Blog.

Is ARN-509 more effective than MDV3100? 

Another interesting compound in prostate cancer drug development is Aragon’s ARN-509.  Recent research published in the AACR journal, “Cancer Research” suggests that ARN-509 may be a more potent androgen-receptor antagonist than MDV3100.

Whether ARN-509 will make it to market remains in question given that Medivation claim the compound was part of the intellectual property it acquired from UCLA along with what became MDV3100.

You can read more about the potential of Aragon’s ARN-509 in prostate cancer on Pharma Strategy Blog.

Radium-223 (Alpharadin) significantly prolongs time to first Skeletal Related Event

Pieter Droppert has written on Biotech Strategy Blog about the radium-223 (Alpharadin) clinical trial data presented by Dr Oliver Sartor at ASCO GU.

Alpharadin is a bone targeted radiopharmaceutical that has shown not only a significant delay in the time to first skeletal related event (SRE) but an increase in overall survival.

Dr Sartor kindly offered some clinical perspective on the data that you can read on Biotech Strategy Blog.

In case you missed it, the video interview with Dr Chris Parker at ECCO/ESMO 2011 in Stockholm offers further information on radium-223 and the ALSYMPCA trial results:

Amgen fails to convince ODAC that Xgeva should have a prostate bone mets indication

If you were following the prostate cancer news this past week, then the ODAC 12:1 vote against granting an indication for denosumab (Xgeva) for the prevention of prostate cancer bone metastases was in the news

Pieter Droppert collated the Xgeva ODAC meeting tweets on Storify if you are interested in what was live tweeted during the meeting.

Once Alpharadin is approved will radiation oncologists now get more involved in the treatment of prostate cancer and how will this impact the market dynamics? Will urologists favor MDV3100 that does not require administration of prednisone at the expense of Zytiga?

Companies will need to adapt their marketing strategy as new prostate cancer new products come to market in 2012.

MDV3100 in Advanced Prostate Cancer

November 9th, 2011


The fast moving prostate cancer market took another leap forward last week with the announcement of positive phase III data for Medivation’s MDV3100.

As reported by Sally Church on Pharma Strategy Blog, Medivation announced that the interim analysis of the AFFIRM trial showed a 4.8 month increase in overall survival (OS) compared to placebo.

Although this is only interim and not final data, Sally observed:

“the 4.8 month improvement in OS in post-chemo setting is superior to that previously seen reported for abiraterone (Zytiga), which had a 3.9 month advantage over placebo.”

Pieter Droppert on Biotech Strategy Blog noted, MDV3100 and Zytiga have completely different mechanisms of action in advanced prostate cancer.

MDV3100 is an androgen receptor blocker, while Zytiga is an androgen biosynthesis inhibitor. This distinction is key.  Zytiga inhibits the CYP17 enzyzme complex required for androgen biosynthesis. However, a consequence of CYP17 inhibition is an increase in mineralocorticoid levels, which can lead to hypokalemia, hypertension, fluid retention.

The result is that Zytiga requires coadministration of a corticosteroid (prednisone) to reduce the incidence and severity of potential mineralocorticoid adverse reactions.

MDV3100 does not require the administration of a steroid, which is a big advantage to patients.  Instead it blocks the androgen receptor (AR) that is highly expressed on prostate cancer cells.

EMCC 2011 Sternberg Challenges to Developing New Advanced Prostate Cancer Drugs 1024x768 MDV3100 in Advanced Prostate CancerCora Sternberg presents Prostate Cancer Educational Symposia at EMCC 2011 in Stockholm

There are a lot of new products in the pipeline for prostate cancer including TAK-700, Cabozantinib (XL184), radium-223 chloride (Alpharadin), BPX-101, Prostvac-VF, ipilumumab, Custirsen (OGX-011), dasatinib (Sprycel), lenalidomide (Revlimid) and ARN-509 to name a few.

The prostate cancer market is forecast to grow from $1B to $5B by 2015 as new products are approved and new treatment options become available. This is good news for advanced prostate cancer patients.

Top posts on Biotech Strategy Blog

October 31st, 2011


Last week, Biotech Strategy Blog celebrated one year of publication!

Top posts on Biotech Strategy Blog Top posts on Biotech Strategy BlogTwo of the most read posts on Biotech Strategy Blog in its first year were:

  • Lucentis v Avastin CATT trial results in AMD (briefing at ARVO)
  • Prostate Cancer Intervention versus Observation (PIVOT) trial data (presented in plenary session at AUA)

You can read more on Biotech Strategy Blog about the top posts of the past year. Some of the topics Pieter Droppert has most enjoyed writing about include: radium-223 (Alpharadin) and use of nanotechnology to detect blast injuries.

We look forward to further coverage of news from medical and scientific congresses on Biotech Strategy Blog as it enters a second year.

Pieter will be at the AACR-NCI-EORTC molecular targets and cancer therapeutics meeting in San Francisco in two weeks time.

Alpharadin may change standard of care for prostate cancer patients with bone mets

September 29th, 2011


We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city.

@MaverickNY top twitter influencer at EMCC2011 Alpharadin may change standard of care for prostate cancer patients with bone mets

Sally Church (@MaverickNY) live tweeted several sessions from the meeting and was name the “Top Twitter Influencer” for the #EMCC2011 hashtag. You can catch up with the tweets fron ECCO ESMO ESTRO 2011 on Pharma Strategy Blog.

Top Influencers of 2011 Stockholm Cancer Congress Alpharadin may change standard of care for prostate cancer patients with bone mets

Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 (Alpharadin) in advanced prostate cancer that was presented in Stockholm.

He also produced a video of the media briefing by Dr Chris Parker from the Royal Marsden Hospital where the ALSYMPCA phase 3 trial results were reviewed.  It is well worth watching!

Please contact us if you would like to learn more about the fast moving Prostate Cancer market and how pharma marketing strategy may be impacted by the new products in development such as radium-223 (Alpharadin), that is on fast track for FDA approval in 2012.

2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer News

September 26th, 2011


It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride.

Stockholm 2011 Multidisciplinary Cancer Congress 300x168 2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer NewsThe phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) in Stockholm this past weekend.

Pieter Droppert has two posts on Biotech Strategy Blog from the Congress about the potentially “practice changing” Alpharadin prostate cancer data:

He also took the opportunity to interview Dr Chris Parker, Consultant Clinical Oncologist at The Royal Marsden Hospital, who presented the ALSYMPCA phase 3 trial results, and a video blog post will follow.

Stockholm Cancer Congress 2011 Social Media 300x169 2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer NewsLive conference twitter board at #EMCC2011 

Sally Church on Pharma Strategy Blog aggregated all the tweets from the 2011 ESMO ECCO congress in Stockholm.  With only a few people tweeting, the twitter stream doesn’t report all the news, but does give a flavor of an excellent cancer meeting with a good balance of science and clinical data.

It’s an exciting time for prostate cancer patients and physicians with multiple new treatment options on the horizon. However, the fast moving and dynamic prostate cancer market is likely to present Pharma/Biotech marketing strategy professionals with opportunities and challenges. Alpharadin is on the fast track to FDA approval in 2012.

Follow coverage of 2011 Stockholm Cancer Congress #EMCC2011

September 22nd, 2011


Stockholm Waterfront 2011 300x169 Follow coverage of 2011 Stockholm Cancer Congress  #EMCC2011The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden.

Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data that is a late breaking abstract.

Sally Church (@MaverickNY) will be covering several sessions live on Twitter. On Pharma Strategy Blog, Sally is aggregating the live tweets from the meeting (#EMCC2011). If you are unable to be in Stockholm for the meeting this weekend, you can follow the action remotely. As Sally would say, “check it out.”

Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

September 17th, 2011


Next week sees the start of the 2011 Stockholm Cancer Congress – a joint multidisciplinary meeting of ECCO, ESMO and ESTRO.

What’s likely to be hot news from Stockholm? On Biotech Strategy Blog, Pieter Droppert has highlighted the phase III data to be presented at ECCO 2011 on Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC).

Screen shot 2011 09 17 at 10.52.12 AM Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

The prostate cancer market is set to become interesting from a commercial and marketing strategy perspective, with several new products in late phase development for CRPC including MDV3100, TAK-700, lenalidomide, Alpharadin, custirsen, Prostvac to name but a few.  The Alpharadin data from the ALSYMPCA trial will be presented as a late breaking abstract in the presidential session on Saturday September 24th.  Based on the interim data previously released, positive data is expected.

The best abstract at ECCO 2011, however, is the data on hedgehog pathway (Hh) inhibitor, vismodegib in advanced basal cell carcinoma (BCC).  This will also be presented in the presidential session on Saturday 24th.

Screen shot 2011 09 17 at 10.51.54 AM Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

Sally Church on Pharma Strategy Blog has written extensively about hedgehog inhibitors and earlier this week wrote about the news that Roche had filed for FDA approval of vismodegib. Given the accolade of “best abstract” and the data presented in the plenary session at the AACR annual meeting earlier this year, we can expect good news for patients who at present have no treatment options.

As Sally notes, vismodegib (GDC-0449) if approved by the FDA, “will offer the first proof of concept for the role of Hedgehog and Smoothend Inhibition in the treatment of cancer.”

AUA 2011 Annual Meeting Prostate Cancer Highlights

May 18th, 2011


AUA 2011 Plenary Banner 300x225 AUA 2011 Annual Meeting Prostate Cancer HighlightsThe 2011 annual meeting of the American Urological Association (AUA) ended in Washington DC today.

Some of the highlights of the meeting were written about on Pharma Strategy Blog and Biotech Strategy Blog, these include:

PIVOT (Prostate Cancer Intervention versus Observation Study)

The data from this study was presented in Tuesday’s plenary session by Dr Tim Wilt, a Professor at the University of Minnesota, and was to many attendees, the highlight of the meeting.

AUA 2011 Wilts PIVOT Conclusion 300x225 AUA 2011 Annual Meeting Prostate Cancer HighlightsThe trial results showed for the first time that radical prostatectomy (RP) is no better than watchful waiting in men with early stage prostate cancer using evidence based medicine.

This groundbreaking research is likely to have a major impact on urology practice in the United States.

Pieter Droppert wrote about the PIVOT results on Biotech Strategy Blog.  Scott Hensley on NPR’s Health Blog, “Shots” references Pieter’s post, and has an interview with Dr Wilt that is also well worth reading.

Also presented at AUA in Tuesday’s plenary session were the results from:

Denosumab (Xgeva®) 147 phase III trial

AUA 2011 Xgeva 147 Study Design 300x225 AUA 2011 Annual Meeting Prostate Cancer HighlightsThis study looked at castrate resistant prostate cancer patients at high risk of development of bone metastasis.

Sally Church on Pharma Strategy Blog discusses the results presented by Dr Matthew Smith at AUA.  Denosumab was shown to increase bone metastasis-free survival and delayed time to first bone metastasis, but did not increase overall survival (OS).

Both Sally Church and Pieter Droppert also wrote additional blog posts from the meeting.  On Biotech Strategy Blog, Pieter wrote about data that showed:

European men with a biochemical recurrence have a lower risk of prostate cancer survival compared to those in the United States

He also wrote about:

New Prostate Cancer products in development beyond the androgen axis

Some of the new products mentioned in Pieter’s post include alpharadin, XL-184 (cabozantinib), Prostvac-VF, BPX-101 and ipilimumab.  You can read more on Biotech Strategy Blog.

Meanwhile on Pharma Strategy Blog, Sally Church continued one of her themes of how social media is impacting medical conferences by reviewing:

How AUA have embraced Social Media in 2011

Sally also recorded a video blog post (vlog) from AUA that highlighted some of the exciting developments in basic biology and how this may lead to new Prostate Cancer treatments in the future.  Click here to watch this.

If you were unable to attend the meeting, Sally aggregated the #AUA2011 tweets.

Selecting what to write about on a blog is subjective, so the above posts are not intended to provide comprehensive meeting or conference coverage, only a few highlights of what was presented at the highly informative and educational AUA annual meeting.

If you are interested in a more comprehensive report on the Prostate Cancer Market and the emerging new products in development, please do not hesitate to contact us.